Knights of Columbus Asset Advisors LLC Sells 802 Shares of Insulet Co. (NASDAQ:PODD)

Knights of Columbus Asset Advisors LLC trimmed its stake in Insulet Co. (NASDAQ:PODD) by 3.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 22,310 shares of the medical instruments supplier’s stock after selling 802 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Insulet were worth $5,824,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of PODD. Victory Capital Management Inc. increased its position in shares of Insulet by 5.1% in the third quarter. Victory Capital Management Inc. now owns 35,706 shares of the medical instruments supplier’s stock worth $8,311,000 after purchasing an additional 1,724 shares during the last quarter. Empowered Funds LLC bought a new position in Insulet during the third quarter valued at approximately $220,000. Natixis Advisors LLC grew its position in Insulet by 34.8% during the third quarter. Natixis Advisors LLC now owns 33,161 shares of the medical instruments supplier’s stock valued at $7,718,000 after acquiring an additional 8,554 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Insulet during the third quarter valued at approximately $2,221,000. Finally, PNC Financial Services Group Inc. grew its position in Insulet by 7.3% during the third quarter. PNC Financial Services Group Inc. now owns 12,969 shares of the medical instruments supplier’s stock valued at $3,019,000 after acquiring an additional 886 shares during the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $268.32 on Friday. The stock has a fifty day moving average of $272.04 and a 200 day moving average of $256.71. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The firm has a market capitalization of $18.84 billion, a price-to-earnings ratio of 46.34, a PEG ratio of 3.62 and a beta of 1.29. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. As a group, research analysts expect that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on PODD shares. Raymond James reiterated an “outperform” rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Canaccord Genuity Group increased their price target on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Citigroup raised their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Finally, JPMorgan Chase & Co. raised their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Buying and Selling at Insulet

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.47% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.